Hashimoto T, Omura K, Ishida F, Watanabe Y
Dept. of Surgery 1, Kanazawa University School of Medicine.
Gan To Kagaku Ryoho. 1993 Aug;20(10):1333-8.
A clinical study of the combination of cis-diamminedichloroplatinum [II] (CDDP) and 5-fluorouracil derivatives was conducted in advanced cancer of the alimentary tract. The regimen consisted of CDDP 50 mg/body/day (day 1-2, continuous infusion), 5-fluorouracil 500-750 mg/body/day (day 2-7, continuous infusion) and UFT 400 mg/day (day 8-28) on 1-3 courses. Thirty patients could be evaluated. The response rate was 25% (2/8) in cases of esophageal cancer, 31% (4/13) in gastric cancer and 33% (3/9) in colorectal cancer, with an overall response rate of 30% (9/30). A comparatively higher response rate was obtained in lymph node metastases (46%) and liver metastases (50%). Anorexia, nausea/vomiting and leukocytopenia were frequently observed, but almost all were well tolerated and recovered except two cases with severe leukocytopenia and nephrotoxicity. Based on these results, this combination chemotherapy seems to be useful for advanced cancer of the alimentary tract.
对顺二氨二氯铂（II）（CDDP）与5-氟尿嘧啶衍生物联合用药进行了一项针对晚期消化道癌的临床研究。该治疗方案包括：CDDP 50mg/体/天（第1 - 2天，持续输注）、5-氟尿嘧啶500 - 750mg/体/天（第2 - 7天，持续输注）以及优福定400mg/天（第8 - 28天），共进行1 - 3个疗程。可对30例患者进行评估。食管癌患者的缓解率为25%（2/8），胃癌患者为31%（4/13），结直肠癌患者为33%（3/9），总体缓解率为30%（9/30）。在淋巴结转移（46%）和肝转移（50%）患者中获得了相对较高的缓解率。经常观察到厌食、恶心/呕吐和白细胞减少，但除两例严重白细胞减少和肾毒性患者外，几乎所有患者耐受性良好且恢复正常。基于这些结果，这种联合化疗似乎对晚期消化道癌有用。
